ATE58060T1 - Pharmazeutische zusammensetzungen. - Google Patents

Pharmazeutische zusammensetzungen.

Info

Publication number
ATE58060T1
ATE58060T1 AT88311290T AT88311290T ATE58060T1 AT E58060 T1 ATE58060 T1 AT E58060T1 AT 88311290 T AT88311290 T AT 88311290T AT 88311290 T AT88311290 T AT 88311290T AT E58060 T1 ATE58060 T1 AT E58060T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
buprenorphine
naltrexone
opiate
effect
Prior art date
Application number
AT88311290T
Other languages
English (en)
Inventor
John William Lewis
Original Assignee
Reckitt & Colmann Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt & Colmann Prod Ltd filed Critical Reckitt & Colmann Prod Ltd
Application granted granted Critical
Publication of ATE58060T1 publication Critical patent/ATE58060T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glass Compositions (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Photoreceptors In Electrophotography (AREA)
AT88311290T 1987-12-03 1988-11-29 Pharmazeutische zusammensetzungen. ATE58060T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878728294A GB8728294D0 (en) 1987-12-03 1987-12-03 Treatment compositions
EP88311290A EP0319243B1 (de) 1987-12-03 1988-11-29 Pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE58060T1 true ATE58060T1 (de) 1990-11-15

Family

ID=10627937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88311290T ATE58060T1 (de) 1987-12-03 1988-11-29 Pharmazeutische zusammensetzungen.

Country Status (9)

Country Link
US (1) US4935428A (de)
EP (1) EP0319243B1 (de)
AT (1) ATE58060T1 (de)
AU (1) AU613993B2 (de)
DE (1) DE3861014D1 (de)
GB (1) GB8728294D0 (de)
IE (1) IE61198B1 (de)
NZ (1) NZ227083A (de)
ZA (1) ZA888885B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
CA2063340A1 (en) * 1991-11-12 1993-05-13 Mahmoud Cherif Assaad Biased pneumatic tire having a belt structure with six annular layers
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
AU782475B2 (en) * 1993-07-27 2005-08-04 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
CA2165802A1 (en) * 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
ATE211906T1 (de) * 1996-03-12 2002-02-15 Alza Corp Zusammensetzung und dosisform mit einem opioid- antagonisten
AU5913098A (en) * 1997-01-13 1998-08-03 Lance L. Gooberman Opiate antagonist implant and process of preparation therefor
PL341309A1 (en) * 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
ATE280579T1 (de) 1999-08-27 2004-11-15 Southern Res Inst Injizierbare buprenorphinhaltige mikrosphärenzusammensetzungen und ihre verwendung zur reduktion von heroin- und alkoholkonsum
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
PT1255547E (pt) 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CA2452872A1 (en) * 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
ES2292775T3 (es) * 2001-07-06 2008-03-16 Penwest Pharmaceuticals Co. Formulaciones de liberacion prolongada de oximorfona.
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
PT1416842E (pt) * 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
PL367427A1 (en) 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
MXPA04009713A (es) 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
ES2361068T3 (es) * 2002-04-23 2011-06-13 Durect Corporation Sistemas analgésicos transdérmicos con potencial de abuso reducido.
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
ES2665999T3 (es) * 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
PL1610791T3 (pl) 2003-03-31 2011-07-29 Titan Pharmaceuticals Inc Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
JP2007527415A (ja) * 2003-10-30 2007-09-27 アルザ・コーポレーシヨン 乱用の可能性が低い経皮鎮痛剤システム
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
WO2006058029A2 (en) * 2004-11-22 2006-06-01 Woolhandler Robert A Method of treating opioid dependency
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
PL1895994T3 (pl) * 2005-05-13 2011-02-28 Alza Corp Wielowarstwowy system podawania leków z barierą zabezpieczającą przed wypływaniem materiału ze zbiornika
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
GB0606124D0 (en) * 2006-03-28 2006-05-03 Reckitt Benckiser Healthcare Buprenorphine derivatives and uses thereof
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
WO2007149438A2 (en) 2006-06-19 2007-12-27 Alpharma, Inc. Pharmaceutical compositions
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447014A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
PE20110422A1 (es) * 2008-07-07 2011-07-01 Euro Celtique Sa Composicion farmaceutica que comprende antagonistas opioides
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
AU2012311293B2 (en) 2011-09-19 2014-02-20 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
UA116567C2 (uk) 2013-07-23 2018-04-10 Євро-Селтік С.А. Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions

Also Published As

Publication number Publication date
EP0319243A1 (de) 1989-06-07
AU613993B2 (en) 1991-08-15
NZ227083A (en) 1991-02-26
ZA888885B (en) 1989-08-30
US4935428A (en) 1990-06-19
IE61198B1 (en) 1994-10-19
IE883595L (en) 1989-06-03
AU2643288A (en) 1989-06-08
EP0319243B1 (de) 1990-11-07
GB8728294D0 (en) 1988-01-06
DE3861014D1 (de) 1990-12-13

Similar Documents

Publication Publication Date Title
ATE58060T1 (de) Pharmazeutische zusammensetzungen.
HK1094148A1 (en) Synergistic therapeutic compositions and methods
NZ223598A (en) Zinc-protamine-alpha interferon complexes and pharmaceutical compositions
EP0695224A4 (de) Zusammensetzungen und verfahren zur behandlung von abfällen
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
GB8814660D0 (en) Compositions for preventing tooth decay
GR3022995T3 (en) Pharmaceutical composition consisting of flupirtin and morphine for the treatment of pain and to avoid a morphine addiction
IL92180A (en) Pharmaceutical composition for preventing or reducing eosinophilia
NZ226634A (en) Substituted piperidine derivatives and analgesic and anesthetic compositions
GB2222768B (en) Analgesic compounds and compositions
PH24723A (en) Device and composition for treatment of the gums
DE68901831D1 (de) Motortreibstoffadditiv und ablagerungen reduzierende motortreibstoffzusammensetzung.
NZ220770A (en) Benzimidazoles and pharmaceutical compositions
GB9101525D0 (en) Improvements in or relating to the protection of needle points
UA41881C2 (uk) Лікарській засіб для лікування або профілактики запалення та спосіб лікування або профілактики запалення (варіанти)
FI884838A0 (fi) Nytt s-timololderivat och foerfarande foer dess framstaellning.
GR900300082T1 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
GB2260702B (en) Improvements relating to the treatment of haemophilia B by subcutaneous injection of factor 1X
GB8416457D0 (en) Device for dosage and injection
ZA881170B (en) Compositions and methods for treating wood
GB8924413D0 (en) Oil waste treatment compositions
GB9023516D0 (en) Fuel oil composition treatment
UA12447A (uk) Спосіб профілактики професійhого броhхіту у робітників пилоhебезпечhих професій з докліhічhими формами хвороби і зhижеhим імуhітетом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee